ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Fabrication of pantoprazole-loaded microsphere clusters with enteric and mucoadhesive properties for enhanced ulcer targeting.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to formulate and evaluate, both in vitro and in vivo, enteric-coated mucoadhesive microspheres of pantoprazole using xanthan gum and Eudragit L100-55 in order to protect pantoprazole from gastric acid degradation and to create a temporary drug reservoir in the gastrointestinal tract, thereby achieving enhanced targeting. The goal was to assess their potential in preventing ketorolac-induced gastric ulcers in rats. Various formulations of pantoprazole microspheres were prepared and developed via an extrusion method using ionotropic gelation and dip coating. The formulations were evaluated for encapsulation efficiency, particle size, mucoadhesive properties, swelling percentage, resistance to gastric acid, and drug release over six hours in vitro. The optimized formulation (10 mg/kg) was subsequently tested in vivo on rats with ketorolac-induced (30 mg/kg) gastric ulcers, and the gastric tissue was examined for histopathological changes. The formulation containing 1% xanthan gum showed the highest drug release (80% w/w) and suitable loading (77.58% w/w), with a swelling index of 50.84% w/w, average particle size of 1.19 mm, an adhesion strength of 2.71 ± 0.87 N per 0.1 g and was fully resistant to acidic conditions. In vivo, it prevented gastric ulcers as effectively as the marketed product and, unlike the marketed product, also prevented vascular rupture in all ketorolac-induced ulcer rats. The optimized formulation performed well, suggesting its potential as an oral delivery alternative.
Indexed as
Identifiers
41632250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.